Seasoned Pharmaceutical Executive Brings 20 Years of Pharmaceutical Product
Development and Commercialization Expertise to Leading Taste Technology Firm
CRANBURY, N.J., Jan. 4 /PRNewswire/ -- Linguagen Corp.
(http://www.linguagen.com), a leader in the development of new compounds to
improve the taste and quality of pharmaceutical, food and beverage products,
announces the appointment of Susan Welsh, MD, MBA, to the position of
President. Dr. Welsh will be responsible for the Company's pharmaceutical
product development efforts as well as the Company's business development
strategy and execution. The appointment highlights Linguagen's progress
advancing its research programs into development and commercial opportunities.
"Dr. Welsh has unusually broad experience ranging from strategic portfolio
creation through managing development and commercialization of novel
pharmaceutical products," said Ray Salemme, Ph.D., CEO of Linguagen Corp. "We
are excited that Dr. Welsh is joining our management team at this crucial
stage of Linguagen's evolution and look forward to her contributions as we
implement our strategy, advance our products, and foster new relationships
with business partners."
Prior to joining Linguagen, Dr. Welsh was Group Vice President, Global
Project Management at Schering-Plough, where she was responsible for all
aspects of global project management including the R&D licensing function. She
also served as a member of Schering-Plough's Pharmaceutical Leadership Board.
Prior to Schering Plough, Dr. Welsh held senior business and pharmaceutical
development positions at Johnson & Johnson, Pharmacia, Syntex, Alza, and
SmithKline Beecham. During her career, Dr. Welsh has spent nearly 20 years in
the management of global pharmaceutical product development and
commercialization. Prior to joining industry, Dr. Welsh served as a
commissioned officer in the Royal Air Force, where she ran acute and
ambulatory care units throughout the world.
Dr. Welsh holds a BSc and an MBChB (Bachelor of Medicine and Bachelor of
Surgery) from the University of Leeds, United Kingdom, an MBA from the
University of California at Berkeley, and a Master's of Information Management
from Washington University. She is on the faculty at Stanford School of
Medicine, and is a Fellow of the Faculty of Pharmaceutical Medicine and Royal
Colleges of Physicians, U.K. She also serves as a member of the Board of
Advisors of the New Jersey Medical School and the National Council, School of
Engineering and Applied Science at Washington University in St. Louis.
About Linguagen
Linguagen Corp. (http://www.linguagen.com) is a biotechnology firm that
identifies and develops compounds to improve the taste of pharmaceutical, food
and beverage products. Linguagen's pharmaceutical program focuses on a unique
biochemical approach to bitterness suppression of medicines that many patients
find unpalatable. Reducing the bitter taste of medicines will expand the range
of formulation options and increase patient compliance. Linguagen's food and
beverage program focuses on identifying flavor enhancers that improve the
taste of existing ingredients, reduce the need for excess sugar and salt, and
which contribute to the development of healthier, better-tasting foods and
beverages.
SOURCE Linguagen Corp.
 back to top
Related links:
http://www.linguagen.com
CONTACT:
Business, Scott M. Horvitz of Linguagen
Corp., +1-609-860-1500, scott.horvitz@linguagen.com; or Media,
Jennifer Garber of Environics Communications for Linguagen Corp.,
+1-203-325-8772, ext. 18, jgarber@environics-usa.com
|
